CStone Pharmaceuticals
HKEX:2616

Watchlist Manager
CStone Pharmaceuticals Logo
CStone Pharmaceuticals
HKEX:2616
Watchlist
Price: 1.81 HKD -0.55%
Market Cap: 2.3B HKD
Have any thoughts about
CStone Pharmaceuticals?
Write Note

CStone Pharmaceuticals
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CStone Pharmaceuticals
Operating Income Peer Comparison

Comparables:
6160
603392
002252
300122
300896

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
CStone Pharmaceuticals
HKEX:2616
Operating Income
-ÂĄ297.2m
CAGR 3-Years
35%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Operating Income
-ÂĄ8.8B
CAGR 3-Years
8%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Operating Income
ÂĄ1.4B
CAGR 3-Years
22%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Operating Income
ÂĄ2.3B
CAGR 3-Years
31%
CAGR 5-Years
46%
CAGR 10-Years
23%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Operating Income
ÂĄ7B
CAGR 3-Years
-7%
CAGR 5-Years
25%
CAGR 10-Years
50%
Imeik Technology Development Co Ltd
SZSE:300896
Operating Income
ÂĄ2.1B
CAGR 3-Years
64%
CAGR 5-Years
71%
CAGR 10-Years
N/A

See Also

What is CStone Pharmaceuticals's Operating Income?
Operating Income
-297.2m CNY

Based on the financial report for Jun 30, 2024, CStone Pharmaceuticals's Operating Income amounts to -297.2m CNY.

What is CStone Pharmaceuticals's Operating Income growth rate?
Operating Income CAGR 5Y
22%

Over the last year, the Operating Income growth was 61%. The average annual Operating Income growth rates for CStone Pharmaceuticals have been 35% over the past three years , 22% over the past five years .

Back to Top